<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02114645</url>
  </required_header>
  <id_info>
    <org_study_id>ZTB-5030</org_study_id>
    <secondary_id>ZTB5030</secondary_id>
    <nct_id>NCT02114645</nct_id>
  </id_info>
  <brief_title>The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes</brief_title>
  <official_title>To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zekai Tahir Burak Women's Health Research and Education Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zekai Tahir Burak Women's Health Research and Education Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered
      in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and
      GnRH antagonist protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective clinical trial evaluates the effect of a two dose GnRH agonist administered
      in the luteal phase on the outcome of ART cycles stimulated with the long GnRH agonist and
      GnRH antagonist protocol. Decision between each of these two protocols was subjective and
      depended on the clinical context.In addition to routine luteal phase support with
      progesterone and estradiol valerate,women received two dose of GnRH agonist on the fifth and
      tenth day after ET.Live birth rate was the primary outcome measure.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>42 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy</measure>
    <time_frame>more than 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>miscarriage</measure>
    <time_frame>up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OHSS</measure>
    <time_frame>up to 10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>LongGnRH agonist protocol(controlgroup)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long protocol-leuprolide acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHantagonist protocol(control group)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>antagonist protocol-leuprolide acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide acetate</intervention_name>
    <description>in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support</description>
    <arm_group_label>Long protocol-leuprolide acetate</arm_group_label>
    <arm_group_label>antagonist protocol-leuprolide acetate</arm_group_label>
    <other_name>lucrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vaginal progesterone</intervention_name>
    <description>crinone gel is applied till fetal heart beat is detected</description>
    <arm_group_label>LongGnRH agonist protocol(controlgroup)</arm_group_label>
    <arm_group_label>Long protocol-leuprolide acetate</arm_group_label>
    <arm_group_label>GnRHantagonist protocol(control group)</arm_group_label>
    <arm_group_label>antagonist protocol-leuprolide acetate</arm_group_label>
    <other_name>crinone gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4 mg oral estradiol valerate</intervention_name>
    <description>estrofem is given twice a day</description>
    <arm_group_label>LongGnRH agonist protocol(controlgroup)</arm_group_label>
    <arm_group_label>Long protocol-leuprolide acetate</arm_group_label>
    <arm_group_label>GnRHantagonist protocol(control group)</arm_group_label>
    <arm_group_label>antagonist protocol-leuprolide acetate</arm_group_label>
    <other_name>estrofem 2mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Couples undergoing ART with their own gametes.

          -  Couples having at least one good embryo available for transfer.

          -  Normoresponder

          -  Infertility etiology is unexplained

          -  ovulation triggered by intramuscular injection of 10000 IU of HCG

        Exclusion Criteria:

        Patients older than 38 years old

          -  High and poor responder patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagihan Cengaver, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nagihan Cengaver, MD</last_name>
    <phone>+905556309298</phone>
    <email>nagihancengaver@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zekai Tahir Burak Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Cankaya</state>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/?term=16926261</url>
    <description>Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2014</study_first_posted>
  <last_update_submitted>April 13, 2014</last_update_submitted>
  <last_update_submitted_qc>April 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zekai Tahir Burak Women's Health Research and Education Hospital</investigator_affiliation>
    <investigator_full_name>Nagihan CENGAVER</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <keyword>Luteal phase support,GnRH agonist,ART cycles</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Deslorelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

